<DOC>
	<DOCNO>NCT01377389</DOCNO>
	<brief_summary>The goal clinical research study learn ipilimumab combination either Lupron® ( leuprolide ) , Zoladex® ( goserelin ) , Firmagon® ( degarelix ) affect prostate-specific antigen ( PSA ) level patient prostate cancer . Researchers also want learn drug combination affect body 's immune system . The safety drug combination also study .</brief_summary>
	<brief_title>Ipilimumab + Androgen Deprivation Therapy Prostate Cancer</brief_title>
	<detailed_description>The Study Drugs : Ipilimumab design block activity cell decrease immune system 's ability fight cancer . Leuprolide , goserelin , degarelix design help stop body make testosterone ( male sex hormone prostate cancer cell need survive ) , may slow growth cancer cell . Study Drug Administration : If find eligible take part study , receive either leuprolide , goserelin degarelix . The drug receive depend doctor think best interest and/or drug insurance provider help cover . Leuprolide give needle muscle . Goserelin degarelix give needle skin abdomen . Beginning Week 1 , receive drug 1 time every month every 3 month 8 month . Your doctor tell dose schedule use . You also receive ipilimumab vein 90 minute Weeks 5 , 9 , 13 , 17 . Your blood pressure measure every 30 minute infusion , well hour finish receive drug . Study Visits : Before dose ipilimumab , every 4 week 6 month last dose ipilimumab , every 12 week , follow test procedure perform : - You physical exam . - You ask drug and/or treatment may receive . - You ask side effect may experience . - Your performance status record . - Blood ( 3 teaspoon ) draw routine test measure protein , PSA , testosterone level , check function pancreas , thyroid , adrenal gland . - Urine collect routine test . - This blood also test hormone level check function thyroid adrenal gland ( dose ipilimumab 4 week last dose ) . Every 12 week , image scan screen . Length Study : You may receive study drug 8 month . You remain study long disease remain stable . You take study treatment intolerable side effect disease get bad . End-of-Study Treatment/Observation Visit : Within 14 day disease get bad , follow test procedure perform : - You physical exam . - You ask drug and/or treatment may receive . - You ask side effect may experience . - Blood ( 3 teaspoon ) draw routine test . This blood also test measure protein , PSA , testosterone level , check function pancreas , thyroid , adrenal gland . - You image scan screen . Long-Term Follow-Up : A member study staff check every 6 month End-of-Study Treatment/Observation Visit . This consist phone call , e-mail , review medical and/or record . If contact phone , call last minute . This investigational study . Leuprolide , goserelin , degarelix FDA approve commercially available treatment prostate cancer . Ipilimumab FDA approve commercially available melanoma . Its use treat prostate cancer investigational . Up 48 patient take part study . All enrol MD Anderson .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Leuprolide</mesh_term>
	<mesh_term>Goserelin</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>1 . Histologically cytologically confirm prostate carcinoma . 2 . Evidence metastatic disease previous bone scan and/or CT scan and/or MRI . 3 . Castratesensitive disease . Patients already ADT eligible long time initiation LHRH analog antagonist great 1 month AND total exposure time LHRH analog antagonist exceed 8 month ( i.e . effectiveness current depot LHRH analog antagonist extend beyond 8 month since initiation ) . 4 . Patients receive prior hormonal therapy allow participate long hormone ablation 1.5 time long : e.g . 1 ) Patients receive 4 month hormonal ablation eligible long hormonal ablation &gt; /= 6 month ; 2 ) Patients receive 1 year hormonal ablation eligible long hormone ablation &gt; /= 18 month ; 3 ) Patients receive 2 year hormonal ablation eligible long hormonal ablation &gt; /= 3 year elapse since discontinuation . 5 . ECOG performance status &lt; /= 1 6 . Patients must normal organ marrow function define : ) WBC &gt; /= 3000/uL ; b ) ANC &gt; /= 1500/uL ; c ) Platelets &gt; /= 100 x 10^3/uL ; ) Hemoglobin &gt; /= 9 g/dL ; e ) Creatinine &lt; /= 2mg/dL ; f ) ALT &lt; /= 2.5 x ULN patient without liver metastasis . For patient liver metastasis ALT &lt; /= 5 x ULN allow ; g ) Bilirubin &lt; /= 3 x ULN ( except patient Gilbert 's Syndrome , must total bilirubin &lt; /= 3mg/dL ) 7 . Patients include study must &gt; /= 18 year old 8 . Ability understand willingness sign write informed consent document . 1 . Autoimmune disease : Patients history inflammatory bowel disease ( include Crohn 's disease ulcerative colitis ) autoimmune disorder rheumatoid arthritis , systemic progressive sclerosis [ scleroderma ] , Systemic Lupus Erythematosus autoimmune vasculitis [ e.g. , Wegener 's Granulomatosis ] exclude study . 2 . Any underlying medical psychiatric condition , opinion Investigator , make administration study drug hazardous obscure interpretation AEs : e.g . condition associate frequent diarrhea chronic skin condition , recent surgery colonic biopsy patient recover , partial endocrine organ deficiency . 3 . Patients know brain metastasis . 4 . Patients small cell carcinoma prostate . 5 . History malignancy , nonmelanoma skin cancer Ta T1 ( low grade ) bladder carcinoma , unless complete remission therapy disease least 5 year . 6 . Uncontrolled intercurrent illness include , limited , ongoing active infection , history congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement . 7 . Known HIV , Hepatitis B , Hepatitis C. 8 . Untreated symptomatic spinal cord compression . 9 . Any nononcology vaccine therapy use prevention infectious disease ( one month prior dose ipilimumab ) . 10 . Concomitant therapy following : IL2 , interferon nonstudy immunotherapy regimens ; cytotoxic chemotherapy ; immunosuppressive agent ; investigation therapy ; chronic use systemic corticosteroid ( used management cancer noncancerrelated illness ) . 11 . Previous participation another ipilimumab clinical trial prior treatment CD137 agonist CTLA4 inhibitor agonist . 12 . History acute diverticulitis , intraabdominal abscess , GI obstruction , abdominal carcinomatosis know risk factor bowel perforation . 13 . Patients agree practice appropriate birth control method therapy . 14 . Concurrent use 5alpha reductase inhibitor ( finasteride dutasteride ) .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Prostate cancer</keyword>
	<keyword>Castrate sensitive prostate carcinoma</keyword>
	<keyword>Metastatic prostate carcinoma</keyword>
	<keyword>Androgen deprivation therapy</keyword>
	<keyword>ADT</keyword>
	<keyword>Prostate-specific antigen</keyword>
	<keyword>PSA</keyword>
	<keyword>Ipilimumab</keyword>
	<keyword>Yervoy</keyword>
	<keyword>BMS-734016</keyword>
	<keyword>MDX010</keyword>
	<keyword>Leuprolide</keyword>
	<keyword>Lupron Depot</keyword>
	<keyword>Leuprolide Acetate</keyword>
	<keyword>Goserelin</keyword>
	<keyword>Zoladex</keyword>
	<keyword>Degarelix</keyword>
	<keyword>Firmagon</keyword>
</DOC>